Cardiac Syndrome X: Update 2014

Cardiology Clinics

Volumn 32, Issue 3, 2014, Pages 463-478

  Agrawal, Shilpa ^a   Mehta, Puja K ^b   Bairey Merz, C Noel ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Angina; Cardiac syndrome X; Ischemia; Microvascular endothelial dysfunction; Myocardial hypersensitivity

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; RANOLAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; XANTHINE DERIVATIVE; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; CLINICAL FEATURE; COGNITIVE THERAPY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; COUNTERPULSATION; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; ELECTROCARDIOGRAPHY; ELECTROSTIMULATION THERAPY; GANGLIONECTOMY; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; LIFESTYLE MODIFICATION; MICROCIRCULATION; NOCICEPTION; PATHOGENESIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; STELLATE GANGLION BLOCK; SYNDROME X; THORAX PAIN; TREATMENT OUTCOME; DIAGNOSTIC IMAGING; HEALTH; HEART MUSCLE REVASCULARIZATION; MICROVASCULAR ANGINA; MORBIDITY; PROCEDURES; TRENDS;

DIAGNOSTIC IMAGING; GLOBAL HEALTH; HUMANS; MICROVASCULAR ANGINA; MORBIDITY; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; VASODILATOR AGENTS;

EID: 84905252372     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2014.04.006     Document Type: Review

References (112)

1. Wachira J.K., Stys T.P. Cardiovascular disease and bridging the diagnostic gap. SD Med 2013, 66(9):366-369.
2. Melikian N., De Bruyne B., Fearon W.F., et al. The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Prog Cardiovasc Dis 2008, 50(4):294-310.
3. Phan A., Shufelt C., Merz C.N. Persistent chest pain and no obstructive coronary artery disease. JAMA 2009, 301(14):1468-1474.
4. Kemp H.G. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973, 32(3):375-376.
5. Parsyan A., Pilote L. Cardiac syndrome X: mystery continues. Can J Cardiol 2012, 28(Suppl 2):S3-S6.
6. Crea F., Lanza G.A. Angina pectoris and normal coronary arteries: cardiac syndrome X. Heart 2004, 90(4):457-463.
7. Humphries K.H., Pu A., Gao M., et al. Angina with "normal" coronary arteries: sex differences in outcomes. Am Heart J 2008, 155(2):375-381.
8. Sullivan A.K., Holdright D.R., Wright C.A., et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994, 308(6933):883-886.
9. Kaski J.C., Rosano G.M., Collins P., et al. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. JAm Coll Cardiol 1995, 25(4):807-814.
10. Jadhav S.T., Ferrell W.R., Petrie J.R., et al. Microvascular function, metabolic syndrome, and novel risk factor status in women with cardiac syndrome X. Am J Cardiol 2006, 97(12):1727-1731.
11. Papanicolaou M.N., Califf R.M., Hlatky M.A., et al. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. Am J Cardiol 1986, 58(13):1181-1187.
12. Kemp H.G., Kronmal R.A., Vlietstra R.E., et al. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. JAm Coll Cardiol 1986, 7(3):479-483.
13. Gulati M., Cooper-DeHoff R.M., McClure C., et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009, 169(9):843-850.
14. Jespersen L., Hvelplund A., Abildstrom S.Z., et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 2012, 33(6):734-744.
15. Sedlak T.L., Lee M., Izadnegahdar M., et al. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. Am Heart J 2013, 166(1):38-44.
16. Camici P.G., Crea F. Coronary microvascular dysfunction. NEngl J Med 2007, 356(8):830-840.
17. von Mering G.O., Arant C.B., Wessel T.R., et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109(6):722-725.
18. Singh M., Singh S., Arora R., et al. Cardiac syndrome X: current concepts. Int J Cardiol 2010, 142(2):113-119.
19. Kaski J.C., Crea F., Nihoyannopoulos P., et al. Transient myocardial ischemia during daily life in patients with syndrome X. Am J Cardiol 1986, 58(13):1242-1247.
20. Patel M.R., Peterson E.D., Dai D., et al. Low diagnostic yield of elective coronary angiography. NEngl J Med 2010, 362(10):886-895.
21. Lanza G.A., Manzoli A., Pasceri V., et al. Ischemic-like ST-segment changes during Holter monitoring in patients with angina pectoris and normal coronary arteries but negative exercise testing. Am J Cardiol 1997, 79(1):1-6.
22. Di Fiore D.P., Beltrame J.F. Chest pain in patients with 'normal angiography': could it be cardiac?. Int J Evid Based Healthc 2013, 11(1):56-68.
23. Fass R., Achem S.R. Noncardiac chest pain: diagnostic evaluation. Dis Esophagus 2012, 25(2):89-101.
24. McConaghy J.R., Oza R.S. Outpatient diagnosis of acute chest pain in adults. Am Fam Physician 2013, 87(3):177-182.
25. Stochkendahl M.J., Christensen H.W. Chest pain in focal musculoskeletal disorders. Med Clin North Am 2010, 94(2):259-273.
26. Beltrame J.F., Crea F., Camici P. Advances in coronary microvascular dysfunction. Heart Lung Circ 2009, 18(1):19-27.
27. Beltrame J.F., Sasayama S., Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. JAm Coll Cardiol 1999, 33(6):1442-1452.
28. Zaya M., Mehta P.K., Merz C.N. Provocative testing for coronary reactivity and spasm. JAm Coll Cardiol 2014, 63(2):103-109.
29. Beltrame J.F. Defining the coronary slow flow phenomenon. Circ J 2012, 76(4):818-820.
30. Kothawade K., Bairey Merz C.N. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol 2011, 36(8):291-318.
31. Shufelt C.L., Thomson L.E., Goykhman P., et al. Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovasc Diagn Ther 2013, 3(3):153-160.
32. Bottcher M., Botker H.E., Sonne H., et al. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation 1999, 99(14):1795-1801.
33. Buchthal S.D., den Hollander J.A., Merz C.N., et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. NEngl J Med 2000, 342(12):829-835.
34. Buffon A., Rigattieri S., Santini S.A., et al. Myocardial ischemia-reperfusion damage after pacing-induced tachycardia in patients with cardiac syndrome X. Am J Physiol Heart Circ Physiol 2000, 279(6):H2627-H2633.
35. Chauhan A., Mullins P.A., Taylor G., et al. Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J 1997, 18(1):60-68.
36. Galassi A.R., Crea F., Araujo L.I., et al. Comparison of regional myocardial blood flow in syndrome X and one-vessel coronary artery disease. Am J Cardiol 1993, 72(2):134-139.
37. Lanza G.A., Buffon A., Sestito A., et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. JAm Coll Cardiol 2008, 51(4):466-472.
38. Meeder J.G., Blanksma P.K., Crijns H.J., et al. Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J 1995, 16(11):1571-1577.
39. Panting J.R., Gatehouse P.D., Yang G.Z., et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. NEngl J Med 2002, 346(25):1948-1953.
40. Tweddel A.C., Martin W., Hutton I. Thallium scans in syndrome X. Br Heart J 1992, 68(1):48-50.
41. Camici P.G., Gistri R., Lorenzoni R., et al. Coronary reserve and exercise ECG in patients with chest pain and normal coronary angiograms. Circulation 1992, 86(1):179-186.
42. Camici P.G., Marraccini P., Lorenzoni R., et al. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. JAm Coll Cardiol 1991, 17(7):1461-1470.
43. Nihoyannopoulos P., Kaski J.C., Crake T., et al. Absence of myocardial dysfunction during stress in patients with syndrome X. JAm Coll Cardiol 1991, 18(6):1463-1470.
44. Panza J.A., Laurienzo J.M., Curiel R.V., et al. Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. JAm Coll Cardiol 1997, 29(2):293-301.
45. Rosano G.M., Kaski J.C., Arie S., et al. Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J 1996, 17(8):1175-1180.
46. Rosen S.D., Uren N.G., Kaski J.C., et al. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994, 90(1):50-60.
47. Maseri A., Crea F., Kaski J.C., et al. Mechanisms of angina pectoris in syndrome X. JAm Coll Cardiol 1991, 17(2):499-506.
48. Lanza G.A., Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 2010, 121(21):2317-2325.
49. Wessel T.R., Arant C.B., McGorray S.P., et al. Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clin Cardiol 2007, 30(2):69-74.
50. Crea F., Camici P.G., Bairey Merz C.N. Coronary microvascular dysfunction: an update. Eur Heart J 2014, 35(17):1101-1111.
51. Shapiro L.M., Crake T., Poole-Wilson P.A. Is altered cardiac sensation responsible for chest pain in patients with normal coronary arteries? Clinical observation during cardiac catheterisation. Br Med J (Clin Res Ed) 1988, 296(6616):170-171.
52. Cannon R.O., Quyyumi A.A., Schenke W.H., et al. Abnormal cardiac sensitivity in patients with chest pain and normal coronary arteries. JAm Coll Cardiol 1990, 16(6):1359-1366.
53. Lagerqvist B., Sylven C., Waldenstrom A. Lower threshold for adenosine-induced chest pain in patients with angina and normal coronary angiograms. Br Heart J 1992, 68(3):282-285.
54. Wielgosz A.T., Fletcher R.H., McCants C.B., et al. Unimproved chest pain in patients with minimal or no coronary disease: a behavioral phenomenon. Am Heart J 1984, 108(1):67-72.
55. Rutledge T., Reis S.E., Olson M., et al. History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain: the WISE study. JAm Coll Cardiol 2001, 37(3):780-785.
56. Beitman B.D. Panic disorder in patients with angiographically normal coronary arteries. Am J Med 1992, 92(5A):33S-40S.
57. Pasceri V., Lanza G.A., Buffon A., et al. Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. JAm Coll Cardiol 1998, 31(1):62-66.
58. Lim T.K., Choy A.J., Khan F., et al. Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology. Cardiovasc Ther 2009, 27(1):49-58.
59. Nossaman V.E., Nossaman B.D., Kadowitz P.J. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiol Rev 2010, 18(4):190-197.
60. Russo G., Di Franco A., Lamendola P., et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther 2013, 27(3):229-234.
61. Larsen W., Mandleco B. Chest pain with angiographic clear coronary arteries: a provider's approach to cardiac syndrome X. JAm Acad Nurse Pract 2009, 21(7):371-376.
62. Frishman W.H. β-Adrenergic blockade in cardiovascular disease. JCardiovasc Pharmacol Ther 2013, 18(4):310-319.
63. Cotrim C., Almeida A.G., Carrageta M. Cardiac syndrome X, intraventricular gradients and, beta-blockers. Rev Port Cardiol 2010, 29(2):193-203.
64. Bugiardini R., Borghi A., Biagetti L., et al. Comparison of verapamil versus propranolol therapy in syndrome X. Am J Cardiol 1989, 63(5):286-290.
65. Leonardo F., Fragasso G., Rossetti E., et al. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia 1999, 44(12):1065-1069.
66. Kalinowski L., Dobrucki L.W., Szczepanska-Konkel M., et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003, 107(21):2747-2752.
67. Sen N., Tavil Y., Erdamar H., et al. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol Derg 2009, 9(5):371-379.
68. Kaski J.C., Rodriguez-Plaza L., Brown J., et al. Efficacy of carvedilol (BM 14,190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol 1985, 56(1):35-40.
69. Parker J.D., Parker J.O. Stable angina pectoris: the medical management of symptomatic myocardial ischemia. Can J Cardiol 2012, 28(Suppl 2):S70-S80.
70. Cannon R.O., Watson R.M., Rosing D.R., et al. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. Am J Cardiol 1985, 56(4):242-246.
71. Sutsch G., Oechslin E., Mayer I., et al. Effect of diltiazem on coronary flow reserve in patients with microvascular angina. Int J Cardiol 1995, 52(2):135-143.
72. Lanza G.A., Colonna G., Pasceri V., et al. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999, 84(7):854-856. A858.
73. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291(3):309-316.
74. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. JAm Coll Cardiol 2004, 43(8):1375-1382.
75. Gould H.J., Garrett C., Donahue R.R., et al. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol 2009, 20(8):755-758.
76. Mehta P.K., Goykhman P., Thomson L.E., et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 2011, 4(5):514-522.
77. Ferrari R., Guardigli G., Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther 2010, 24(4):331-339.
78. Kaski J.C., Rosano G., Gavrielides S., et al. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. JAm Coll Cardiol 1994, 23(3):652-657.
79. Nalbantgil I., Onder R., Altintig A., et al. Therapeutic benefits of cilazapril in patients with syndrome X. Cardiology 1998, 89(2):130-133.
80. Chen J.W., Hsu N.W., Wu T.C., et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002, 90(9):974-982.
81. Pauly D.F., Johnson B.D., Anderson R.D., et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2011, 162(4):678-684.
82. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. NEngl J Med 1995, 332(8):488-493.
83. Kayikcioglu M., Payzin S., Yavuzgil O., et al. Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 2003, 24(22):1999-2005.
84. Fabian E., Varga A., Picano E., et al. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol 2004, 94(5):652-655.
85. Zhang X., Li Q., Zhao J., et al. Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X. Coron Artery Dis 2014, 25(1):40-44.
86. Elliott P.M., Krzyzowska-Dickinson K., Calvino R., et al. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart 1997, 77(6):523-526.
87. Emdin M., Picano E., Lattanzi F., et al. Improved exercise capacity with acute aminophylline administration in patients with syndrome X. JAm Coll Cardiol 1989, 14(6):1450-1453.
88. Yoshio H., Shimizu M., Kita Y., et al. Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. JAm Coll Cardiol 1995, 25(7):1547-1551.
89. Lanza G.A., Gaspardone A., Pasceri V., et al. Effects of bamiphylline on exercise testing in patients with syndrome X. GItal Cardiol 1997, 27(1):50-54.
90. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83(3):389-400.
91. Cannon R.O., Quyyumi A.A., Mincemoyer R., et al. Imipramine in patients with chest pain despite normal coronary angiograms. NEngl J Med 1994, 330(20):1411-1417.
92. Cox I.D., Hann C.M., Kaski J.C. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998, 19(2):250-254.
93. Moore R.K., Groves D.G., Bridson J.D., et al. Abrief cognitive-behavioral intervention reduces hospital admissions in refractory angina patients. JPain Symptom Manage 2007, 33(3):310-316.
94. Potts S.G., Lewin R., Fox K.A., et al. Group psychological treatment for chest pain with normal coronary arteries. QJM 1999, 92(2):81-86.
95. Arora R.R., Chou T.M., Jain D., et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. JAm Coll Cardiol 1999, 33(7):1833-1840.
96. Kronhaus K.D., Lawson W.E. Enhanced external counterpulsation is an effective treatment for syndrome X. Int J Cardiol 2009, 135(2):256-257.
97. Frobert O., Molgaard H., Botker H.E., et al. Autonomic balance in patients with angina and a normal coronary angiogram. Eur Heart J 1995, 16(10):1356-1360.
98. Gulli G., Cemin R., Pancera P., et al. Evidence of parasympathetic impairment in some patients with cardiac syndrome X. Cardiovasc Res 2001, 52(2):208-216.
99. de Vries J., Dejongste M.J., Durenkamp A., et al. The sustained benefits of long-term neurostimulation in patients with refractory chest pain and normal coronary arteries. Eur J Pain 2007, 11(3):360-365.
100. Lanza G.A., Sestito A., Sandric S., et al. Spinal cord stimulation in patients with refractory anginal pain and normal coronary arteries. Ital Heart J 2001, 2(1):25-30.
101. Moore R., Groves D., Hammond C., et al. Temporary sympathectomy in the treatment of chronic refractory angina. JPain Symptom Manage 2005, 30(2):183-191.
102. Wong C.W., Wang C.H., Wen M.S., et al. Effective therapy with transthoracic video-assisted endoscopic coagulation of the left stellate ganglion and upper sympathetic trunk in congenital long-QT syndrome. Am Heart J 1996, 132(5):1060-1063.
103. Drott C. Results of endoscopic thoracic sympathectomy (ETS) on hyperhidrosis, facial blushing, angina pectoris, vascular disorders and pain syndromes of the hand and arm. Clin Auton Res 2003, 13(Suppl 1):I26-I30.
104. Methangkool E., Chua J.H., Gopinath A., et al. Anesthetic considerations for thoracoscopic sympathetic ganglionectomy to treat ventricular tachycardia storm: a single-center experience. JCardiothorac Vasc Anesth 2014, 28(1):69-75.
105. Moss A.J., McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. NEngl J Med 1971, 285(16):903-904.
106. Eriksson B.E., Tyni-Lenne R., Svedenhag J., et al. Physical training in syndrome X: physical training counteracts deconditioning and pain in syndrome X. JAm Coll Cardiol 2000, 36(5):1619-1625.
107. Tyni-Lenne R., Stryjan S., Eriksson B., et al. Beneficial therapeutic effects of physical training and relaxation therapy in women with coronary syndrome X. Physiother Res Int 2002, 7(1):35-43.
108. Anand S.S., Islam S., Rosengren A., et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008, 29(7):932-940.
109. Asbury E.A., Slattery C., Grant A., et al. Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause 2008, 15(3):454-460.
110. Gokce N., Vita J.A., McDonnell M., et al. Effect of medical and surgical weight loss on endothelial vasomotor function in obese patients. Am J Cardiol 2005, 95(2):266-268.
111. Raitakari O.T., Adams M.R., McCredie R.J., et al. Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann Intern Med 1999, 130(7):578-581.
112. O'Keefe J.H., Gheewala N.M., O'Keefe J.O. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. JAm Coll Cardiol 2008, 51(3):249-255.